Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
Recent Articles
In Myeloma, New Drugs, Skyrocketing Price Tags
In late February, seven pharmaceutical executives were called before the U.S. Senate Finance Committee to testify about the prices of brand-name prescription drugs, which...
Are New Treatment Options for Beta-Thalassemia Ready for Widespread Use?
Patients with transfusion-dependent beta-thalassemia, the most severe form of the disease, require lifelong management with red blood cell (RBC) transfusions, presenting a substantial cost...
Quality of Generic Drugs Manufactured Overseas Comes into Question
The passage of the Hatch-Waxman Act in 1984, which created a regulatory track for generic drugs, marked the beginning of the generic-drug boom in...
Who Foots the Surprise Bill?
As U.S. Senators prepare for a July vote on proposed legislation that would protect patients from surprise medical bills, three key players in the...
Current Issue
May 2019, Volume 5, Issue 6
This issue features a look at home-based care for hematologic disorders, strides in pediatric leukemia in El Salvador, and more.
